Rydén Anna, Sörstadius Elisabeth, Bergenheim Klas, Romanovschi Alexandru, Thorén Fredrik, Witt Edward A, Sternhufvud Catarina
AstraZeneca, Mölndal, Sweden.
AstraZeneca, Mississauga, Canada.
PLoS One. 2016 Nov 3;11(11):e0164977. doi: 10.1371/journal.pone.0164977. eCollection 2016.
Diagnoses of Type 1 Diabetes Mellitus (T1DM) in Europe appear to be on the rise. Therefore it is imperative that researchers understand the potential impact that increases in prevalence could have on the affected individuals as well as on society as a whole. Accordingly this study examined the humanistic and economic burden of T1DM in patients relative to those without the condition across a number of health outcomes including health status, work productivity loss, activity impairment, and healthcare resource use.
Survey data from a large, representative sample of EU adults (The EU National Health and Wellness Survey) were examined.
Results suggest that overall burden is higher for those diagnosed with T1DM than respondents without diabetes and that burden increases as complications associated with T1DM increase.
Taken together, these results suggest that treatment strategies for T1DM should balance clinical, humanistic, and economic burden and patients should be educated on the role of complications in disease outcomes.
欧洲1型糖尿病(T1DM)的诊断数量似乎在上升。因此,研究人员必须了解患病率上升可能对受影响个体以及整个社会产生的潜在影响。相应地,本研究考察了T1DM患者相对于非T1DM患者在包括健康状况、工作生产力损失、活动受限和医疗资源使用等多项健康结果方面的人文和经济负担。
研究分析了来自欧盟成年人的大型代表性样本(欧盟国家健康与福祉调查)的调查数据。
结果表明,被诊断为T1DM的患者的总体负担高于未患糖尿病的受访者,并且随着与T1DM相关的并发症增加,负担也会加重。
综合来看,这些结果表明,T1DM的治疗策略应平衡临床、人文和经济负担,并且应该让患者了解并发症在疾病转归中的作用。